Serentis Inc., a UK drug startup formed by former Arakis Ltd. executives, has acquired Surface Therapeutics Ltd., a developer of treatments for dermatological diseases. No financial terms were disclosed. Serentis recently raised Gbp10.3 million in Series A funding from firms like NovoAS, MVM Life Science Partners and Apposite Capital. www.serentis-pharma.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.